All In MedTech

FDA Clearance Tracker · P170019-S045

FoundationOne CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 25, 2024

Approved

Time to decision

342 days

Received May 19, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P170019-S045
Device name
FoundationOne CDx
Applicant location
Boston, MA
Received
May 19, 2023
Decided
Apr 25, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P170019

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

approval for the migration of the F1CDx from the HiSeq 4000 to NovaSeq 6000 configuration

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.